Overexpression of Matrix Metalloproteinase-21 is Associated with Poor Overall Survival of Patients with Colorectal Cancer

Journal of Gastrointestinal Surgery

Volumn 15, Issue 7, 2011, Pages 1188-1194

  Huang, Yi ^a   Li, Wenhai ^b   Chu, Dake ^a   Zheng, Jianyong ^a   Ji, Gang ^a   Li, Mengbin ^a   Zhang, Hongwei ^a   Wang, Weizhong ^a   Du, Jianjun ^a   Li, Jipeng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Invasion; Matrix metalloproteinase 21; Prognosis

Indexed keywords

MATRIX METALLOPROTEINASE; MMP21 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; CHINA; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME;

CHINA; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958834678     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1519-5     Document Type: Article

References (46)

1. Jianping Wang. Current and future situation of colorectal carcinoma screening. Journal of Digestive Surgery 2006; 5: 303-305.
2. Fang SG, Yang JZ, Yang F. Clinical characteristics of 610 cases with multiple primary malignant neoplasm's in digestive tract. Shijie Huaren Xiaohua Zazhi 1999; 7: 812.
3. Wang MR, Guo CH, Li MS, et al. A case-control study on the dietary risk factors of upper digestive tract cancer. Zhonghua Liuxingbingxue Zazhi 1999; 20: 95-97.
4. Yu BM, Zhao R. Molecular biology of colorectal carcinoma. Shijie Huaren Xiaohua Zazhi 1999; 7: 173-175.
5. Chen SY, Wu TF, Liu HY, et al. Hospital-based ten-year data of gastroendoscopy. Shijie Huaren Xiaohua Zazhi 1999; 7: 15-17.
6. Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-403.
7. Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 1999; 181: 393-409.
8. Brown R S, Wahl R L. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 1993: 2979-2985.
9. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. Br J Surg. 1997; 84: 160-6.
10. Curran S, Murray GI. Matrix metalloprteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-30.
11. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
12. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
13. Park HI, Ni J, Gerkema FE, et al. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275: 20540-4.
14. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 2001; 10: 383-92.
15. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93.
16. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-8.
17. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev Cancer Metastasis Rev 1990; 9: 289-303.
18. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70.
19. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99-106.
20. McDonnell S, Navre M, Coffey RJ Jr, et al. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991; 4: 527-33.
21. Pyke C, Ralfkiaer E, Tryggvason K, et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-65.
22. Yoshimoto M, Itoh F, Yamamoto H, et al. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614-8.
23. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase-9 mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996; 74: 1161-7.
24. Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133-40.
25. Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-96.
26. Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-6.
27. Ring P, Johansson K, Höyhtyä M, et al. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage. Br J Cancer 1997; 76: 805-11.
28. Oberg A, Höyhtyä M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20: 1085-91. (not differentiation survival, stage).
29. Sis B, Saǧol O, Küpelioǧlu A, et al. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004; 200: 379-87.
30. Pesta M, Topolcan O, Holubec L Jr, et al. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27: 1863-7.
31. Cho YB, Lee WY, Song SY, et al. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 2007; 38: 1603-10.
32. Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-23.
33. Ahokas K, Lohi J, Lohi H, et al. Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer. Gene 2002; 301: 31-41.
34. Ahokas K, Lohi J, Illman SA, et al. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest 2003; 83: 1887-99.
35. Kuivanen T, Ahokas K, Virolainen S, et al. MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Arch 2005; 447: 954-60.
36. Boyd S, Virolainen S, Pärssinen J, et al. MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. Exp Dermatol. 2009; 18: 1044-52.
37. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen recep tors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-130.
38. Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-34.
39. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12: 1184-91.
40. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
41. Peng ZR, Zhong WH, Liu J, Xiao PT. Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells. Undersea Hyperb Med 2010; 37: 141-50.
42. Coskun U, Yamac D, Gulbahar O, et al. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 2007; 54: 348-52.
43. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104: 504-11.
44. Tamatani T, Azuma M, Ashida Y, et al. Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 2004; 108: 912-21.
45. Chu D, Zhang Z, Li Y, et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer 2010 Oct 18.
46. Kyllönen H, Pasanen AK, Kuittinen O, et al. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. Leuk Lymphoma 2009; 50: 1301-7.